TBPH - Theravance Biopharma Inc
IEX Last Trade
8.25
0.040 0.485%
Share volume: 237,152
Last Updated: Fri 30 Aug 2024 09:59:54 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$8.21
0.04
0.49%
Fundamental analysis
23%
Profitability
15%
Dept financing
17%
Liquidity
75%
Performance
20%
Performance
5 Days
1.98%
1 Month
-17.99%
3 Months
-2.83%
6 Months
-12.23%
1 Year
-15.64%
2 Year
-8.33%
Key data
Stock price
$8.25
DAY RANGE
$8.09 - N/A
52 WEEK RANGE
$7.44 - $11.71
52 WEEK CHANGE
-$0.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Rick Winningham
Region: US
Website:
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Recent news